转甲状腺素蛋白心脏淀粉样变的诊断与治疗研究进展
Research advances in diagnosis and treatment of transthyretin cardiac amyloidosis
汪月 1张俊峰1
作者信息
- 1. 200011 上海,上海交通大学医学院附属第九人民医院心内科
- 折叠
摘要
转甲状腺素蛋白心脏淀粉样变是由于转甲状腺素蛋白沉积于心脏所引起的心脏功能障碍,既往被认为是一种罕见病,其发病隐匿、进展迅速、致死率高.近年来,随着诊断技术的进步,该病的检出率不断提高,各种小分子药物的不断问世也改变了以往无药可医的局面,使其死亡率有所下降.本文主要归纳了近年来转甲状腺素蛋白心脏淀粉样变在诊断和治疗方面的最新进展.
Abstract
Transthyretin cardiac amyloidosis(ATTR-CA)has been considered as a rare cardiac dysfunction with occult onset,rapid progression and high mortality,caused by the accumulation of transthyretin fibrils in the myocardium.Recently,with the development of diagnostic techniques,its detection rate has been increasing.The continuous emergence of various small molecule drugs has also changed the previous situation of lacking therapeutic agents,and its mortality has been reduced.This paper mainly summarizes the latest advances in the diagnosis and treatment of ATTR-CA in recent years.
关键词
淀粉样变/心肌病/转甲状腺素/转甲状腺素蛋白心脏淀粉样变/心脏磁共振/小分子药物Key words
amyloidosis/cardiomyopathy/transthyretin/transthyretin cardiac amyloidosis/cardiac magnetic resonance/small molecule drug引用本文复制引用
基金项目
九院临床研究助力计划(JYLJ202014)
出版年
2024
国家科技期刊平台
NSTL
万方数据